标题
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
作者
关键词
-
出版物
EUROPEAN JOURNAL OF NEUROLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-02-14
DOI
10.1111/ene.13936
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis
- (2018) Johannes Lorscheider et al. Multiple Sclerosis Journal
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
- (2018) Mathias Granqvist et al. JAMA Neurology
- Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis
- (2018) Johannes Lorscheider et al. Multiple Sclerosis Journal
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
- (2016) Damiano Baroncini et al. Multiple Sclerosis Journal
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- Comparative efficacy of fingolimod vs natalizumab
- (2016) Laetitia Barbin et al. NEUROLOGY
- Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
- (2016) Damiano Baroncini et al. Multiple Sclerosis Journal
- Brain health: time matters in multiple sclerosis
- (2016) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
- (2015) Tomas Kalincik et al. ANNALS OF NEUROLOGY
- Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
- (2015) L. Kappos et al. NEUROLOGY
- A changing treatment landscape for multiple sclerosis: challenges and opportunities
- (2014) F. Piehl JOURNAL OF INTERNAL MEDICINE
- A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort
- (2013) O. Outteryck et al. EUROPEAN JOURNAL OF NEUROLOGY
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
- (2011) David B. Clifford ARCHIVES OF NEUROLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More